Top Markets
Coin of the day
Rhinomed Limited Rhinomed Limited

Rhinomed Limited

RNO
Rankning i aktier #35584
Headquartered in Cremorne, Australia, Rhinomed Limited is a global enterprise... Headquartered in Cremorne, Australia, Rhinomed Limited is a global enterprise dedicated to the research, development, and market introduction of consumer and medical devices. Since its incorporation in 2004, the company has focused on creating wearable nasal technologies designed to optimize breathing, improve sleep quality, support general health, and assist in disease diagnosis. Its product offerings include the Turbine, which enhances athletic breathing; Mute, aimed at reducing snoring and promoting clearer airflow; Pronto, a vapor inhaler developed to aid airflow and sleep; and Rhinoswab, utilized for efficient nasal sample collection. Beyond these products, Rhinomed is actively engaged in developing programs across diverse fields such as sleep architecture, the cognitive impact of sleep and respiratory function, obstructive sleep apnea, pain and nausea relief, respiratory diseases, and advanced diagnostics and sensors. The company also provides a distinct drug delivery platform specifically for cannabinoid formulations. Formerly known as Consegna Group Limited, the company adopted the name Rhinomed Limited in November 2013.
Aktiekurs
$0.0260778
Senast synkroniserad: 2024-02-16
Marknadsvärde
$3.69M
Förändring (1 dag)
-0.09%
Förändring (1 år)
0.00%
Land
AU
Handel Rhinomed Limited (RNO)

Kategori

Vinst för Rhinomed Limited (RNO)
Vinst i 2026 TTM: 0
Enligt de senaste finansiella rapporterna från Rhinomed Limited är företagets nuvarande vinst 0. År 2026 hade företaget en vinst på 0, lika med vinsten år 2026 som var 0. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Rhinomed Limited från 2026 till 2026
Vinst vid slutet av varje år
År Vinst Ändra
Inte tillräckligt med data för de angivna datumen.
Vinst för liknande företag eller konkurrenter
Företag Vinst Skillnad i vinst Land
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US